Abstract
Three major lines of drugs have been developed or are under development for the treatment of Alzheimer Disease (AD): cholinergic drugs (mainly cholinesterase inhibitors), anti-beta-amyloid drugs, estrogens and anti-inflammatories. Cholinesterase inhibitors are the only drugs presently approved in USA and Europe for the indication of AD.
Cholinesterase inhibitors tested in clinical trials in Europe, USA and Japan include less than ten drugs, however most of these compounds have advanced to clinical trials III. Based on results related to a population of over 8,000 patients we conclude that several of these compounds have shown significant clinical efficacy and safety in the treatment of Alzheimer disease. There are, however, differences with regard to side effects. The major clinical effect is stabilization of cognitive function during a six- to 12-months period with a parallel improvement of behavioral symptoms. Long-term effect of cholinesterase inhibitors extending to a two year-period has been reported. Future applications of these drugs are treatment of other types dementias such as Lewy body dementia, vascular dementia and Down Syndrome dementia. Combination of cholinesterase inhibitors with estrogens, anti-oxidants and anti-inflammatories may represent a further improvement of the therapy. From the economical point of view, treatment with cholinesterase inhibitors is not cost neutral.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anand R, Hartman R, Messina J, et al (1998) Long-term treatment with rivastigmine continue to provide benefits for up to one year. Fifth Int Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneva, Abstract 18
Becker E, Giacobini E (1988) Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type. Drug Devel Res 12: 163 – 195
Becker R, Moriearty P, Unni L (1991) The second generation of cholinesterase inhibitors: clinical and pharmacological effects. In: Becker R, Giacobini E, Cholinergic basis for Alzheimer therapy. Birkhauser, Boston, 263 – 296
Becker R, Colliver JA, Markwell SJ, et al (1996a) Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor for Alzheimer disease. Alzheimer Dis Assoc Disord 1: 124 – 131
Becker R, Moriearty P, Unni L, et al (1996b) Cholinesterase inhibitors as therapy in Alzheimer’s disease: benefit to risk considerations in clinical application. In: Becker R, Giacobini E, Alzheimer Disease: from molecular biology to therapy. Birkhauser, Boston, 257 – 266
Bowen DM (1983) Biochemical assessment of neurotransmitter and metabolic dysfunction and cerebral atrophy in Alzheimer’s disease. In: Branbury Report 15: Biological aspects of Alzheimer’s disease. Cold Spring Harbor Lab, 219–231
Cummings JL, Cyrus PA, Ruzicka BB, et al (1999) The efficacy of metrifonate in improving the behavioral disturbances of Alzheimer’s disease patients. Am Acad Neurol 524: 004
Davis KL, Mohs RC, Marin D, et al (1999) Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281: 1401 – 1406
DeKosky ST, Harbaugh RE, Schmitt FA, et al (1992) Cortical biopsy in Alzheimer’s disease: diagnostic accuracy and neurochemical, neuropathological and cognitive correlations. Ann Neurol 32: 625 – 632
Frolich L, Dirr A, Gotz E, et al (1998) Acetylcholine in human CSF: methodological considerations and levels in dementia of Alzheimer type. J Neural Transm 105: 961– 973
Geula C, Mesulam MM (1994) Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Terry RD, Katzman R, Bick KL (eds) Alzheimer disease. Raven Press, New York, 263 – 291
Giacobini E (1994) Cholinomimetic therapy of Alzheimer disease: does it slow down deterioration? In: Racagni G, Brunellos N, Langer SZ (eds) Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction. International Academy of Biomedical Drug Research. Karger, New York, 51 – 57
Giacobini E (1995) Cholinesterase inhibitors: from preclinical studies to clinical efficacy in Alzheimer disease. In: Quinn D, Balasubramaniam AS, Doctor BP, Taylor P (eds), Enzymes of the cholinesterase family. Plenum Press, New York, 463– 469
Giacobini E (1996) Cholinesterase inhibitors do more than inhibit cholinesterase. In: Becker R, Giacobini E, Alzheimer disease: from molecular biology to therapy. Birkhauser, Boston, 187 – 204
Giacobini E (2000) Cholinesterases and cholinesterase inhibitors. Basic, preclinical and clinical aspects. M. Dunitz, London
Giacobini E, Cuadra G (1994) Second and third generation cholinesterase inhibitors: from preclinical studies to clinical efficacy. In: Giacobini E, Becker R, Alzheimer disease: therapeutic strategies. Birkhauser, Boston, 155 – 171
Giacobini E, Becker R, Mcilhany M, Kumar V (1988) Intracerebroventricular administration of cholinergic drugs: preclinical trials and clinical experience in Alzheimer patients. In: Giacobini E, Becker R, Current research in Alzheimer therapy. Taylor and Francis, New York, 113 – 122
Gorman DG, Read S, Cummings JL (1993) Cholinergic therapy of behavioral disturbances in Alzheimer’s disease. Neuropsychiatry Neuropsychol Behav Neurol 6: 229 – 234
Greaney M, Marshall D, During M, et al (1992) Ultrasensitive measurement of acetylcholine release in the conscious human hippocampus and anesthetized rat striatum using microdialysis. Soc Neurosci Abstr 2: 137
E. Giacobini: Present and future of Alzheimer therapy
Imbimbo BP, Lucchelli PE (1994) A pharmacodynamic strategy to optimize the clinical response to eptastigmine. In: Becker R, Giacobini E, Alzheimer disease: therapeutic strategies. Birkhauser, Boston, 223 – 230
Inestrosa N, Alvarez A, Perez CA, et al (1996) Acetylcholinesterase accellerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron 16: 881 – 891
Kishnai PS, Sullivan JA, Walter KW, et al (1999) Cholinergic therapy for Down’s syndrome. Lancet 353: 1064 – 1065
Krupp LB, Elkins LE, Scott SR, et al (1999) Donepezil for the treatment of memory impairment in Multiple Sclerosis. Neurology 52 [Suppl 2]: Abstr 137
Lahiri DK, Lewis S, Farlow MR (1994) Tacrine alters the secretion of beta-amyloid precursor protein in cell lines. J Neurosci Res 8: 777 – 787
Mohs R, Doody R, Morris J, et al (1999) Donepezil preserves functional status in Alzheimer’s disease patients: results from a 1-year prospective placebo-controlled study. Eur Neuropsychopharm 9 [Suppl 5]: S328
Mori F, Lai CC, Fusi F, Giacobini E (1995) Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neurol Rep 6: 633 – 636
Morris JC, Cyrus PA, Orazem J, et al (1998) Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease. Neurology 50: 1222 – 1230
Relkin N, Orazem J, McRae T (1999) The effect of concomitant donepezil and estrogen treatment on the cognitive performance of women with Alzheimer’s disease. 51st Ann Meeting Am Acad Neurology: Abstr 50
Saez-Valero J, Sberna G, Small DH (1998) The beta-amyloid protein regulates acetylcholinesterase expression, assembly and glycosylation in cell culture, APP transgenic mice an the Alzheimer brain. Sixth Int. Meeting on Cholinesterases, La Jolla: Abstr 6
Schenk D, Barbour R, Dunn W, et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (8): 173 – 177
Spencer CM, Noble S (1998) Rivastigmine. A review of its use in Alzheimer’s disease. Drugs Aging 13 (5): 391 – 411
Thai L, Fuld PA, Masur DM, et al (1983) Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol 13: 491 – 496
Tohgi H, Abe T, Hashiguchi K, et al (1994) Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia. Neurosci Lett 177: 139 – 142
Tune L, Brandt J, Frost JJ, et al (1991) Physostigmine in Alzheimer’s disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography. Acta Psychiatr Scand 366: 61 – 65
Wimo A, Winblad B, Grafstrom M (1998) The social consequences for families with Alzheimer disease patients: potential impact of new drug treatment. Int J Geriatr Psych 14: 338 – 347
Winblad B, Engedal K, Soininen H, et al (1999) Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one-year, double- blind trial in patients with mild to moderate Alzheimer’s disease. Ninth Congress of the Int Psychogeriatric Association, Vancouver, Abstr 155
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag/Wien
About this paper
Cite this paper
Giacobini, E. (2000). Present and future of Alzheimer therapy. In: Jellinger, K., Schmidt, R., Windisch, M. (eds) Advances in Dementia Research. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6781-6_24
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6781-6_24
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83512-8
Online ISBN: 978-3-7091-6781-6
eBook Packages: Springer Book Archive